In vivo conversion of dopamine neurons in mouse models of Parkinson's disease - a future approach for regenerative therapy?
(2021) In Current Opinion in Genetics & Development 70. p.76-82- Abstract
Recent advances in cell reprogramming have made it possible to form new therapeutic cells within the body itself via a process called direct conversion or lineage reprogramming. A series of studies have shown that it is possible to reprogram resident glia into new neurons within the brain parenchyma. These studies opened up for the targeted attempts to achieve functional brain repair using in vivo conversion. Because of the relatively focal degeneration, Parkinson's Disease (PD) is an attractive target for both transplantation-based and in vivo conversion-based reparative approaches. Fetal cell transplants have provided proof-of-concept and stem cell-based therapies for PD are now on the verge of entering clinical trials. In the future,... (More)
Recent advances in cell reprogramming have made it possible to form new therapeutic cells within the body itself via a process called direct conversion or lineage reprogramming. A series of studies have shown that it is possible to reprogram resident glia into new neurons within the brain parenchyma. These studies opened up for the targeted attempts to achieve functional brain repair using in vivo conversion. Because of the relatively focal degeneration, Parkinson's Disease (PD) is an attractive target for both transplantation-based and in vivo conversion-based reparative approaches. Fetal cell transplants have provided proof-of-concept and stem cell-based therapies for PD are now on the verge of entering clinical trials. In the future, in vivo conversion may be an alternative to transplantation-based therapies.
(Less)
- author
- Parmar, Malin LU ; Björklund, Anders LU and Björklund, Tomas LU
- organization
- publishing date
- 2021-10-01
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Current Opinion in Genetics & Development
- volume
- 70
- pages
- 76 - 82
- publisher
- Elsevier
- external identifiers
-
- scopus:85109407104
- pmid:34175529
- ISSN
- 1879-0380
- DOI
- 10.1016/j.gde.2021.06.002
- language
- English
- LU publication?
- yes
- id
- ab85f2f1-432b-43d3-bedc-03b0b1144e52
- date added to LUP
- 2021-08-03 15:36:00
- date last changed
- 2024-08-10 18:38:52
@article{ab85f2f1-432b-43d3-bedc-03b0b1144e52, abstract = {{<p>Recent advances in cell reprogramming have made it possible to form new therapeutic cells within the body itself via a process called direct conversion or lineage reprogramming. A series of studies have shown that it is possible to reprogram resident glia into new neurons within the brain parenchyma. These studies opened up for the targeted attempts to achieve functional brain repair using in vivo conversion. Because of the relatively focal degeneration, Parkinson's Disease (PD) is an attractive target for both transplantation-based and in vivo conversion-based reparative approaches. Fetal cell transplants have provided proof-of-concept and stem cell-based therapies for PD are now on the verge of entering clinical trials. In the future, in vivo conversion may be an alternative to transplantation-based therapies.</p>}}, author = {{Parmar, Malin and Björklund, Anders and Björklund, Tomas}}, issn = {{1879-0380}}, language = {{eng}}, month = {{10}}, pages = {{76--82}}, publisher = {{Elsevier}}, series = {{Current Opinion in Genetics & Development}}, title = {{In vivo conversion of dopamine neurons in mouse models of Parkinson's disease - a future approach for regenerative therapy?}}, url = {{http://dx.doi.org/10.1016/j.gde.2021.06.002}}, doi = {{10.1016/j.gde.2021.06.002}}, volume = {{70}}, year = {{2021}}, }